No Data
No Data
Express News | Biomea Fusion To Feature Presentations At 18th International Conference on Advanced Technologies & Treatments for Diabetes Mar. 18-20
Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes
Biomea Fusion Price Target Cut to $16.00/Share From $128.00 by D. Boral Capital
D. Boral Capital Initiates Biomea Fusion(BMEA.US) With Buy Rating, Announces Target Price $16
Biomea Fusion to Become Diabetes, Obesity Medicines Company
Express News | Biomea Fusion: Based on Most Recent Trial Results, Strategic Focus for Icovamenib Will Be in Metabolic Disorders